Sarkoidozun Yaygınlığının Değerlendirilmesinde FDG PET/BT Bulguları ile Nötrofil/Lenfosit Oranının Karşılaştırılması.

Aim: The decision of treatment in sarcoidosis is made based on clinical and radiological findings and changes in pulmonary function test findings during follow-up, and more useful tools are needed. F-18 fluorodeoxyglucose (18F-FDG) positron required important tomography/computed tomography (PET/CT) contains information about the extent of sarcoidosis. Neutrophil/lymphocyte ratio (NLR) opens as a prognostic marker for inflammation. This study evaluated the relationship between the 18F-FDG PET/CT findings of sarcoidosis and NLR and other clinical findings. Patients and Methods: The data of patients who were diagnosed with sarcoidosis after 18F-FDG PET/CT scan in our clinic between January 2017 and December 2019 were reviewed retrospectively. Patients' age, gender, NLR values, smoking status, extrathoracic involvement and symptoms, and 18F-FDG PET/CT findings were compared. Results: This study consisted of 41 patients. There were strong correlations between NLR and whole body total lesion glycolysis (TLG), and moderate correlation between MAIA (r values: 0.852, 0.660, both of them p value: <0.001, respectively). There were significant differences between thoracic involvement and extrathoracic involvement with MAIA, TLG and NLR values (p values,: 0.002, 0.001 and, 0.003, respectively). According to the symptoms of the patients, there was no significant difference between the groups with SUVmax, MAIA, TLG and NLR values. Median values were found to be significantly higher in the elderly group (p values: 0.037 and 0.040, respectively). Were no significant differences in both PET/CT parameters and NLR values. Conclusion: The close relationship between the NLR value, which is accepted as a prognostic indicator in sarcoidosis, and the 18F-FDG PET/CT findings which show the involvement of the disease in the whole body, may provide the clinicians with significant benefits in treatme nt management. [ABSTRACT FROM AUTHOR]